Safety & Toxcity Testing
Proprietary Multiparametric Biomarker Assay for Chemical Safety Testing
The increasing incidence of skin and respiratory allergies is raising concern over the safety of the ever-expanding range of products introduced into the European and US markets. New European legislation will require the testing of all products and raw materials for skin and respiratory safety. Ideally these tests will be performed in cultured human cells, though currently there are no validated alternates to testing using experimental animals.
Proteome Sciences has developed a number of novel products and services for chemical compound safety testing
that can demonstrate if a substance induces irritation or would produce allergies when they come into contact with the skin or the respiratory system. Learn more
|Chemical safety testing
||Cultured skin lineage cells
SensiDerm TMT-SRM 8-Plex is a multiplexed biomarker assay for testing the allergenic potential of chemical compounds and raw materials used in the manufacture of cosmetics, pharmaceuticals, foodstuffs and other household materials such as cleaning agents. Based on the established principles of Selected Reaction Monitoring Mass Spectrometry the differential expression of eight proteins in response to chemical exposure has been shown to correlate with the safety profile of known compounds.
The SensiDerm 8-Plex Assayoffers these advantages:
- Does not use animal model testing
- Applicable to a wide range of potential allergens and irritants – suitable for testing products from many and diverse industries
- Rapid and reproducible results
- Quantitative and accurate high performance mass spectrometry assay
- Assays available through ISO 9001:2008 accredited testing facility
Fill out the form to the right to learn more about SensiDerm 8-Plex Assay and our Biomarkers Discovery Services.
These tests were developed under “Sens-it-iv”s a European Commission-funded project which brings together companies and academic institutions with the aim of developing in vitro alternatives to animal tests, which are currently used for the risk assessment of potential skin or lung sensitizers. As well as reducing the use of animal testing, the programme is aimed at improving consumer safety and benefiting the environment.
Proteome Sciences was invited to join the Sens-it-iv project in 2009 to introduce a new proteomic biomarker approach to allergy testing. Progress has been rapid, with over 200 novel biomarkers discovered and patents filed for allergy testing in the immune system and skin cells. Development of the first eight TMT-SRM assays was completed in November 2011 in only four weeks. The assays have shown excellent performance and correlation with the discovery data.
SensiDermTMT-SRM 8-Plex Assay
SensiDerm TMT-SRM 8-Plex is a multiparametric biomarker test for testing the allergenic potential of chemical compounds and raw materials used in the manufacture of cosmetics, pharmaceuticals, foodstuffs and other household materials such as cleaning agents. The assay uses Selected Reaction Monitoring (SRM) Mass Spectrometry to monitor the concentration of eight selected proteins in response to chemical exposure which have been shown to correlate with the safety profile of known compounds. We are currently validating SensiDerm TMT-SRM 8-plex using a blinded panel of approved un-known compounds provided by the Sens-it-iv consortium.
To perform the SensiDerm TMT-SRM 8-plex assay human keratinocyte-derived cell line MUTZ3 is exposed to compounds and the relative abundance of the eight marker proteins determined and reported independently. Proteome Sciences has pre-determined the relative expression profiles most commonly associated with exposure to allergenic, irritant and safe compounds respectively.